Ciba/Sandoz will urge non-exclusive licenses for Viagene gene therapy patents -- EC merger clearance.
Executive Summary
CIBA/SANDOZ TO SUPPORT NON-EXCLUSIVE LICENSING OF VIAGENE PATENTS relating to brain cancer gene therapy as part of the European Commission's July 17 approval of the merger of Ciba and Sandoz to form Novartis. Ciba and Sandoz "will use their influence as a shareholder of Chiron to support the granting of non-exclusive licenses under certain gene therapy patents of Viagene," the companies stated. Ciba holds a 49% stake in Chiron, which acquired Viagene in 1995.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth